Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Introduction
Osteoporosis is a degenerative skeletal disorder characterized by an increase in bone fragility and fracture risk due to a loss of bone mass and microarchitectural deterioration. The most serious clinical expression of osteoporosis is fracture. Despite the availability of a number of drugs capable of reducing fracture risk by over 50%, the use of drugs to prevent bone loss remains inadequate.

Scope
Epidemiology of osteoporosis in the seven major markets by disease severity, identification of niche populations and unmet needs
Detailed profiles of drugs in late-stage development examining clinical data, patient potential, marketing factors, satisfaction of unmet needs
Primary research with key osteoporosis opinion leaders providing insight on future market entrants and innovative R&D projects in the disease area
Evaluation of key company activity in this market looking at lifecycle management among current leaders and R&D commitments of future players
Highlights
Bisphosphonates will remain the gold-standard approach to osteoporosis treatment due to familiarity among prescribers, genericization of leading brands and innovations in dosing among novel products. Other antiresorptive agents will significant potential be limited by high costs, safety concerns and inadequate commercial development plans.

The osteoporosis pipeline is top-heavy, with 50% of drug candidates in Phase III or higher. Investment is evident across therapeutic classes, particularly in improving peptide delivery methods, although anabolic therapies are dominated by early-Phase PTH drugs and comprise only one-fifth of total pipeline candidates.

Datamonitor has identified the five most promising compounds in development for osteoporosis which together will account for nearly 80% of revenues from pipeline products in 2015. The overriding trend in these top brands is long-interval, intermittent dosing that aims to address the need for improved patient compliance.

Reasons to Purchase
Appreciate key trends in the approach to osteoporosis treatment and prevention and identify opportunities in areas of unmet need
Quantify the commercial potential of therapeutic drug classes and key products and understand the reasons for success
Understand the impact of genericization in the market and the future challenges faced by novel therapies

Introduction
Osteoporosis is a degenerative skeletal disorder characterized by an increase in bone fragility and fracture risk due to a loss of bone mass and microarchitectural deterioration. The most serious clinical expression of osteoporosis is fracture. Despite the availability of a number of drugs capable of reducing fracture risk by over 50%, the use of drugs to prevent bone loss remains inadequate.

Scope
Epidemiology of osteoporosis in the seven major markets by disease severity, identification of niche populations and unmet needs
Detailed profiles of drugs in late-stage development examining clinical data, patient potential, marketing factors, satisfaction of unmet needs
Primary research with key osteoporosis opinion leaders providing insight on future market entrants and innovative R&D projects in the disease area
Evaluation of key company activity in this market looking at lifecycle management among current leaders and R&D commitments of future players
Highlights
Bisphosphonates will remain the gold-standard approach to osteoporosis treatment due to familiarity among prescribers, genericization of leading brands and innovations in dosing among novel products. Other antiresorptive agents will significant potential be limited by high costs, safety concerns and inadequate commercial development plans.

The osteoporosis pipeline is top-heavy, with 50% of drug candidates in Phase III or higher. Investment is evident across therapeutic classes, particularly in improving peptide delivery methods, although anabolic therapies are dominated by early-Phase PTH drugs and comprise only one-fifth of total pipeline candidates.

Datamonitor has identified the five most promising compounds in development for osteoporosis which together will account for nearly 80% of revenues from pipeline products in 2015. The overriding trend in these top brands is long-interval, intermittent dosing that aims to address the need for improved patient compliance.

Reasons to Purchase
Appreciate key trends in the approach to osteoporosis treatment and prevention and identify opportunities in areas of unmet need
Quantify the commercial potential of therapeutic drug classes and key products and understand the reasons for success
Understand the impact of genericization in the market and the future challenges faced by novel therapies